Amplia Therapeutics, a clinical-stage biotechnology company, recently presented the findings of its lead drug candidate, AMP945, in a preclinical model of pancreatic cancer. The results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of only 10%. It is often diagnosed at an advanced stage, making it difficult to treat. Current treatment options include surgery, chemotherapy, and radiation therapy, but these treatments have limited efficacy and can cause significant side effects.
AMP945 is a small molecule inhibitor of the protein Hsp27, which is overexpressed in many types of cancer, including pancreatic cancer. Hsp27 plays a role in cancer cell survival and resistance to chemotherapy, making it an attractive target for cancer therapy.
In the preclinical study, AMP945 was tested in a mouse model of pancreatic cancer. The results showed that treatment with AMP945 significantly reduced tumor growth and increased survival compared to control mice. The drug was well-tolerated and did not cause any significant side effects.
The study also investigated the mechanism of action of AMP945. The researchers found that the drug inhibited the activity of Hsp27, leading to increased apoptosis (cell death) in cancer cells. This suggests that AMP945 could be effective in treating other types of cancer that overexpress Hsp27.
The findings of this preclinical study are promising and support further development of AMP945 as a potential treatment for pancreatic cancer. Amplia plans to initiate a phase 1 clinical trial of AMP945 in patients with advanced solid tumors later this year.
In addition to AMP945, Amplia is developing other small molecule inhibitors of Hsp27 for the treatment of cancer. The company’s pipeline also includes drugs targeting other proteins involved in cancer cell survival and proliferation.
Overall, the presentation of the findings of AMP945 in a preclinical model of pancreatic cancer is an important step forward in the development of new treatments for this deadly disease. Further research is needed to confirm the efficacy and safety of AMP945 in human clinical trials, but the preclinical data is promising and suggests that AMP945 could be a valuable addition to the current treatment options for pancreatic cancer.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Minting the Future w Adryenn Ashley. Access Here.
- Buy and Sell Shares in PRE-IPO Companies with PREIPO®. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: https://platohealth.ai/amplia-reports-amp945-data-in-preclinical-model-of-pancreatic-cancer/